On Tuesday, 31st August 2021, the company Johnson and Johnson said, the company’s experimental vaccine have been failed for providing enough protection against the HIV in the continent of Africa to the young women, who are at more risk of getting infected by HIV.
The failure of the trial has been highlighting the challenges of the development of novel corona virus, especially for the Human Immuno Deficiency Virus, that has not been approved by the vaccines.
Paul Stoffels, chief scientific officer of Johnson and Johnson, said, the HIV has been a unique and more complex virus that has been posed unprecedented challenges for the development of the HIV vaccine due to the ability of the vaccine for hijacking and attacking along with evading the immune system of the human beings.
The testing of the novel corona virus vaccine has been including the participation of the 2,600 women across the five different countries of South Africa, where the women and the girls have been accounted for more than 60 percent of the all new HIV infections in the year 2020, and the trial of the vaccine, that has been based on the design of adenovirus, which the novel corona virus vaccine of Johnson and Johnson have also been using, and it has also been supported by the National Institute of Allergy and Infectious Diseases and also the Bill & Melinda Gates Foundation.
This study is not going to continue, and based on the collected data, Johnson and Johnson said, the participants in the study, that has been confirmed about the results and the company has also been told whether they have received a vaccine.
